Overview
The Best of Targeted Therapies of Lung Cancer (TTLC) 2025 Webinar is designed to bring the data on relevant targets for new therapies to the researchers and healthcare professionals who treat patients with thoracic malignancies and to ensure their understanding of the data on preclinical and early clinical trials for each of the drugs directed against relevant targets.
- Understand current data and controversies in first-line treatment options for metastatic EGFR mt lung cancer.
- Understand data on neoadjuvant, perioperative, and adjuvant systemic treatment options for resected NSCLC and the pros and cons of various approaches.
- Understand novel directions in immunotherapy for lung cancer.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- Understand current data and controversies in first-line treatment options for metastatic EGFR mt lung cancer.
- Understand data on neoadjuvant, perioperative, and adjuvant systemic treatment options for resected NSCLC and the pros and cons of various approaches.
- Understand novel directions in immunotherapy for lung cancer.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Share
Participants
Rebecca Heist
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Antoinette Wozniak
MD
Professor of Medicine and Interim Chief of the Division of Hematology / Oncology
University of Pittsburgh
Shirish Gadgeel
MD
Committee Member
Henry Ford Cancer Institute/Henry Ford Health System
Natasha Leighl
MD
Thoracic Medical Oncology Group Lead
Princess Margaret Cancer Centre
Jonathan Riess
MD,MS
Director, Thoracic Oncology
UC Davis Cancer Center
